Incidence and risk factors for surveillance failure in patients with regular hepatocellular carcinoma surveillance

被引:14
作者
Sinn, Dong Hyun [1 ,2 ]
Yi, Jieun [1 ]
Choi, Moon Seok [1 ]
Choi, Dongil [3 ,4 ]
Gwak, Geum-Youn [1 ]
Paik, Yong-Han [1 ]
Lee, Joon Hyeok [1 ]
Koh, Kwang Cheol [1 ]
Paik, Seung Woon [1 ]
Yoo, Byung Chul [1 ]
机构
[1] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr, Seoul 135710, South Korea
[2] Inje Univ, Sch Med, Sanggye Paik Hosp, Dept Med, Seoul, South Korea
[3] Sungkyunkwan Univ, Dept Radiol, Sch Med, Seoul 135710, South Korea
[4] Sungkyunkwan Univ, Ctr Imaging Sci, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea
关键词
Hepatocellular carcinoma; Surveillance; Ultrasonography; Alpha-fetoprotein; Failure; CIRRHOTIC-PATIENTS; EARLY-DIAGNOSIS; PROGRAM; VIRUS;
D O I
10.1007/s12072-013-9462-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Initial presentation of hepatocellular carcinoma (HCC) at an advanced stage in patients under a regular surveillance program is a devastating problem. Aims We assessed the prevalence and factors associated with this surveillance failure. Methods A total of 304 HCC patients who received regular surveillance were retrospectively reviewed. Surveillance failure was defined when the tumor was diagnosed at beyond the Milan criteria. Results Surveillance failure rate was 5.9 %. Macronodular cirrhosis (MC), ultrasonography-only surveillance (US-S) and infiltrative tumor type were independent factors associated with surveillance failure. The surveillance failure rate was higher in patients with MC (10.3 vs. 3.2 %, p = 0.022), US-S (14.6 vs. 4.3 %, p = 0.013) and when the tumor was infiltrative type (57.1 vs. 2.1 %, p < 0.001). Based on the two baseline factors (MC and US-S), the surveillance failure rates were 35.7, 6.8, 5.9 and 2.6 % for MC(+)/US-S(+), MC(+)/US-S(-), MC(-)/US-S(+) and MC(-)/US-S(-), respectively (p < 0.001). Conclusion The HCC surveillance failure was not rare in clinical practice. These data suggest that special attention for surveillance failure might be needed for patients with MC who receive US-S.
引用
收藏
页码:1010 / 1018
页数:9
相关论文
共 22 条
[21]  
Zoli M, 1996, CANCER-AM CANCER SOC, V78, P977, DOI 10.1002/(SICI)1097-0142(19960901)78:5<977::AID-CNCR6>3.3.CO
[22]  
2-Y